

# Lung adenocarcinoma with active pulmonary tuberculosis: a case report of successful immunotherapy and systematical review

Jinhe Xu (✉ [Xujinhe2019@163.com](mailto:Xujinhe2019@163.com))

Fujian Medical University <https://orcid.org/0000-0003-2681-9893>

**Xiuhua Lin**

900th Hospital of PLA

**Wei Liu**

900th Hospital of PLA

**Jia Ye**

900th Hospital of PLA

**Feilai Xie**

900th Hospital of PLA

**Huimin Deng**

900th Hospital of PLA

**Ming Deng**

900th Hospital of PLA

**Zongyang Yu**

900th Hospital of PLA

---

## Research Article

**Keywords:** lung adenocarcinoma, Immune checkpoint inhibitors (ICIs), tuberculosis (TB), Pembrolizumab, case report

**Posted Date:** September 28th, 2021

**DOI:** <https://doi.org/10.21203/rs.3.rs-936584/v1>

**License:** © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

# Abstract

Immune checkpoint inhibitors (ICIs) have become widely used in the treatment of several malignancies, and get better clinical benefits in some patients with non-small cell lung cancer (NSCLC). However, in most of high-quality clinical Randomized Controlled Trial (RCT) studies, only selected patients are needed. In Real-World Study (RWS), patients contracted simultaneously with NSCLC and Tuberculosis are common. TB reactivation during ICIs use is increasingly recognized and reported. Whether ICIs can be used in anti-tumor in patients with TB are rarely seen. Herein, we present a 67-year-old male active tuberculosis complicated with advanced non-small cell lung cancer (NSCLC) ALK-negative, EGFR wild, and PD-L1 immunohistochemistry (IHC) strongly positive in 60–90% of tumor cells, on ongoing treatment with Pembrolizumab as a first-line anti-tumor therapy during anti-TB treatment. After two cycles of Pembrolizumab, the tumor response was evaluated PR, and TB well controlled. The patient is still on anti-TB and ICIs anti-tumor therapy, sputum smear and sputum culture remain negative, follow-up showed no relapse of tuberculosis infection or tumor progression. Our case shows that it may be feasible to combine anti-TB with ICIs for advanced lung cancer patients with active TB.

## Background

According to the 2017 World Health Organization (WHO) global Mycobacterium tuberculosis (TB) report<sup>[1]</sup>, around one-quarter of the world's population is infected with TB bacilli. Lung Cancer (LC) is also highly prevalent in less well-developed countries. The 2020 Globocan project<sup>[2]</sup> reported an estimated 2.2 million new cases of lung cancer globally. Immune checkpoint inhibitors (ICIs) are a type of cancer immunotherapy that has provided a tremendous breakthrough in the field of oncology<sup>[3]</sup>. But, in clinical studies of immunotherapy for LC, patients with TB have been largely excluded. ICIs-mediated modulation of the immune response has been reported to cause immunerelated infectious complications<sup>[4]</sup>. Also, TB reactivation during their use is increasingly recognized and reported<sup>[5]</sup>. However, there are not many reports about whether ICIs can be used in patients with TB reactivation or LC complicated with TB was diagnosed. The present study reports a case of an advanced lung adenocarcinoma with high Programmed cell death protein ligand 1 (PD-L1) expression complicated with active TB who was treated with anti-TB therapy and responded to Pembrolizumab monotherapy.

## Case Presentation

A 67-year-old male patient, without smoking history, with type 2 Diabetes mellitus and hypertension for 6 months. Due to progressive left limb weakness, he visited the local hospital on June 25, 2020 for head chest computed tomography (CT) examination and found intracranial space occupying complicated with brain edema. The patient suffered from left limb weakness, but presented without fever, cough, chest pain, headache, or weight loss. He had already received radiation treatment for intracranial lesions at other hospitals. He was transferred to our hospital for further diagnosis and treatment. We performed a physical examination of the patient upon admission. Her body temperature was 36.5 °C, ECOG 1 stage.

During admission, she underwent routine blood, sputum, pleural fluid, urine, and stool laboratory tests. Except  $\gamma$ -interferon release from Mycobacterium tuberculosis was positive (143.6pg/ml), no obvious abnormality was found in other blood samples. 18F-FDG PET-CT scans showed (Fig. 1A): Multiple patchy and nodular soft tissue density shadow in the right apex of lung, massive density shadow in the dorsal segment of right lower lobe with cavity formation, and the possibility of inflammatory granuloma tuberculosis was considered. And gastric body thickening, considering the possibility of malignant tumor. Therefore, CT-guided percutaneous lung puncture biopsy and gastroscopy were completed, but no neoplastic lesions were observed. Meanwhile, sputum culture showed positive Mycobacterium tuberculosis. The patient was diagnosed with active TB, then HRZE (isoniazid 0.3, qd, rifampin 0.45, qd, pyrazinamide 1.0, qd, and ethambutol 0.75, qd) anti-TB therapy was given. The sputum smear and sputum culture were negative after 3 months of anti-TB, but CT scans showed an enlarged lower right pulmonary lesion (Fig. 1B), and large ulcers form in the stomach body was seen under gastroscopy. We did a needle biopsy of the patient's lung and gastric area again on November 16, 2020. Histological examination (HE) of the right lung lesion indicated that the patient had non-small cell lung cancer (NSCLC) with a possibility of transforming into adenocarcinoma (Fig. 2). Immunohistochemistry revealed that antigen Ki-67 (60%), thyroid transcription factor 1 (TTF-1) (+++), and Napsin A (+) were positive, while programmed death-ligand 1 (PD-L1)(60%) was negative. Molecular pathology showed that the combined detection results of 10 mutant genes were wild type (EGFR, ALK, ROS1, RET, MET, KRAS, BRAF, HER2, NARS, PIK3CA). The pathological result of gastric body biopsy was also from lung malignant tumor. Based on the above results and observations, the patient was diagnosed with TB, target gene mutation-negative and PD-L1 high expression stage  $\geq$  lung adenocarcinoma (T2bN3M1c, IVB), accompanied by gastric, lymph node and brain metastases.

After being diagnosed, the patient received Pembrolizumab as an anti-tumor treatment followed by oral HRZE as anti-TB treatment. After 2 cycles of Pembrolizumab, the efficacy of tumor was evaluated as partial remission (PR) (Fig. 1C). And the patient achieved complete remission of gastric lesions (CR). Until July 06, 2021, the patient has received 8 cycles of Pembrolizumab, with only hepatotoxic adverse reactions, which can be recovered after active liver-protecting therapy (Fig. 4). His focus remains stable, and sputum smear and sputum culture remain negative, follow-up showed no relapse of tuberculosis infection or tumor progression.

## Discussion And Conclusions

LC has been the most common cancer and the leading cause of cancer-related death worldwide for several decades. And a population-based study about Global patterns and trends in lung cancer incidence showed<sup>[6]</sup> the risks among recent generations have various degrees of increasing in many countries. In the past decade, significant advances have been made in the science of non-small cell lung cancer (NSCLC). In addition to conventional chemotherapy, the treatment of lung cancer has also evolved with the introduction of several lines of tyrosine kinase inhibitors (TKIs) in patients with EGFR, ALK, ROS1, and NTRK mutations. Furthermore, ICIs have dramatically changed the treatment outlook for NSCLC. LC

complicated with pulmonary tuberculosis is a special group, and most of these patients are excluded from the research on ICIs. Recent research has shown that antibiotic-induced disruption of the microbiota may impact ICI efficacy<sup>[7-10]</sup>. A systematic review and meta-analysis of study displayed<sup>[11]</sup> that despite the high heterogeneity between studies, OS still revealing a significantly reduced survival in patients with NSCLC exposed to antibiotics. And the effect seems to depend on the time window of exposure with stronger effects reported when the patients took antibiotics within 60 days around ICIs initiation<sup>[11]</sup>. However, there are no separate studies on the efficacy of between anti-TB therapy and immunotherapy<sup>[12]</sup>.

According to the Tuberculosis Treatment Guidelines<sup>[13]</sup>, patients with active TB should be treated as soon as possible. Our patient's sputum culture was positive for *Mycobacterium tuberculosis*, which met the diagnostic criteria of active TB. We gave him intensive anti-TB therapy for 3 months, but CT showed that the focus in the lung was larger than before (Fig. 1A, 1B). The patient underwent a second lung biopsy, and he was eventually diagnosed with lung adenocarcinoma and active TB. But his genetic tests suggested that there were no target mutations that could benefit. Considering that his high expression of ICIs and excluding the absolute contraindication, he was given to Pembrolizumab at the same time of anti-TB. After 2 cycles of treatment, we made a comprehensive evaluation of him, and found that the primary lesions of the lung, stomach, lymph nodes were significantly reduced (Fig. 1, 3), the curative effect evaluation reached PR.

To further elucidate the impact of anti-TB on the efficacy of ICIs, we perform a systematic review of the literature using PubMed, EMBASE and meeting proceedings. Finally, ten cases were included together with the case reported in this report (Table 1). Of the ten cases included, eight were male and two were female with a median age of 63.7. The underlying malignancies consisted of six cases of adenocarcinoma (ADC), two cases of melanoma, one case of oral squamous cell cancer (SCC) and one case of Merkel cell carcinoma (MCC). Five were treated with pembrolizumab while five were treated with nivolumab. After treatment concurrently with anti-TB and ICIs, one patient developed immune-related adverse events (irAEs) Sjogren's syndrome, one patient developed irAEs adrenal insufficiency, four patients developed irAEs low-grade toxic hepatic, two patients were not occurred irAEs and two patients were not documented irAEs. Except for two cases whose specific information could not be obtained (Table 2), sputum smear and sputum culture of TB were negative in six cases when ICIs was started. For the total anti-TB course, except for one case who had been treated for more than 4 years when the case was reported, the choice was between 6 and 8 months (the median time was 8.6 months). In terms of treatment outcome, CR was obtained in two cases, PR was obtained in four cases, SD was obtained in 1 case, and PD was obtained in one case.

Table 1  
Baseline characteristics of included patients.

Study	Cancer	Age	Sex	ICI	Adverse Reaction
Ours	ADC	67	Male	Pembrolizumab	toxic hepatic
Takata <sup>[19]</sup>	ADC	75	Male	Nivolumab	None
Chu <sup>[20]</sup>	ADC	59	Male	Nivolumab	None
Eeden <sup>[21]</sup>	ADC	56	Female	Nivolumab	diarrhea
Inthasot <sup>[22]</sup>	ADC	69	Male	Nivolumab	NA
	ADC	60	Male	Nivolumab	toxic hepatic
Kim <sup>[18]</sup>	Melanoma	65	Female	Pembrolizumab	Sjögren's syndrome
He <sup>[14]</sup>	Melanoma	50	Male	Pembrolizumab	toxic hepatic
Picchi <sup>[15]</sup>	SCC	53	Male	Pembrolizumab	NA
Tetik Kurt <sup>[16]</sup>	MCC	83	Male	Pembrolizumab	Adrenal insufficiency
Daniel <sup>[17]</sup>					toxic hepatic

ADC, Adenocarcinoma; MCC, Merkel cell carcinoma; SCC, squamous cell carcinoma; NA, not available.

Table 2. Treatment of TB and outcome.

Study	ECOG	TB treatment	Time to ICI reinitiation	TB test results when ICI using	TB course	Outcome
He <sup>[14]</sup>	0	HRZE→RIPE	3m	□	8m	CR
Ours	1	HRZE	3m	□	8m	PR
Takata <sup>[19]</sup>	1	HRZE→RIPE	4m	□	12m	PR
Daniel <sup>[22]</sup>	1	HRZE	4m	□	9m	PR
Tetik Kurt <sup>[21]</sup>	1	NA	When tumor recurrence	NA	>4 years	CR
Kim <sup>[18]</sup>	1	NA	1m	□	NA	SD
Chu <sup>[20]</sup>	2	NA	1m	□	6m	PR
Eeden <sup>[16]</sup>	3	HRZE	Symptoms are slightly relieved	Synchronous treatment soon led to death due to tumor progression		PD
Inthasot <sup>[17]</sup>				NA		
Picchi <sup>[15]</sup>						

CR, Complete Response; PR, Partial Response; SD, Stable Disease; PD, Progressive Disease; NA, not available; HRZE, Isoniazide+ Rifampin+ Pyrazinamide+ Ethambutol; RIPE, streptomycin + ethambutol +moxifloxacin; □, negative.

Summary analysis shows that anti-TB has no obviously effect on the efficacy of ICIs, with seven of the eight cases that could be analyzed achieving good results. For suitable populations selected by anti-TB combined ICIs, ECOG scores between 0 and 2 are more recommended, and generally good treatment outcomes can be achieved. When ECOG is over 2, combination therapy is not recommended, because it may accelerate disease progression. The main adverse reactions of anti-TB combined with ICIs are mainly hepatotoxicity, and the liver function can be maintained normal after liver protection therapy. According to WHO guidelines<sup>[23, 24]</sup>, normal anti-TB treatment takes at least 6 months, but further clinical studies are needed to determine whether anti-TB treatment should be extended when combined with immunotherapy. And further research is needed on the timing of drug combination.

Conclusion, It can be found from our article that anti-TB may have little effect on ICIs, and it is worthwhile to conduct a larger cohort study in the future to verify the effect of anti-TB on ICIs.

## Declarations

### Funding

This work was supported by grants from the Foundation of Priority Project of Science and Technology Plan of Fujian Province (No. 2014Y0037), and the Clinical Key Specialty Construction Project of Fujian Province (No. 2015-593 and No. 2017YZ0001-2).

**Competing interests:** The authors have no conflicts of interest to declare.

**Availability of data and materials:** The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

**Code availability:** Not applicable.

**Authors' contributions:** Jin X, Xiu L, Wei L and Zong Y conceived and designed the research. Jia Y, Fei X, Hui D, and Ming D analyzed the data. Jin X, Xiu L, Wei L and Zong Y contributed materials/analysis tools. Jin X, Xiu L, Wei L and Zong Y wrote the paper. All authors read and approved the final manuscript.

**Ethics approval and consent to participate:** All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee(s) and with the Helsinki Declaration (as revised in 2013). Written informed consent was obtained from the patient.


**Consent for publication:** The authors have consented to publication.

## References

1. Adigun R, Singh R, Tuberculosis. 2020 Oct 27. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. PMID: 28722945.
2. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2021;71(3):209–49.
3. Darvin P, Toor SM, Sasidharan Nair V, et al. Immune checkpoint inhibitors: recent progress and potential biomarkers. *Exp Mol Med*. 2018; 13;50(12):1–11.
4. Takata S, Koh G, Han Y, Yoshida H, et al. Paradoxical response in a patient with non-small cell lung cancer who received nivolumab followed by anti-Mycobacterium tuberculosis agents. *J Infect Chemother*. 2019;25(1):54–8.
5. Suliman AM, Bek SA, Elkhatim MS, et al. Tuberculosis following programmed cell death receptor-1 (PD-1) inhibitor in a patient with non-small cell lung cancer. Case report and literature review. *Cancer Immunol Immunother*. 2021;70(4):935–44.
6. Zhang Y, Luo G, Etxeberria J, et al. Global patterns and trends in lung cancer incidence: a population-based study. *J Thorac Oncol*. 2021;16(6):933–94.
7. Pinato DJ, Howlett S, Ottaviani D, et al. Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer. *JAMA Oncol*. 2019;15(12):1774–8.
8. Yoon MY, Yoon SS. Disruption of the Gut Ecosystem by Antibiotics. *Yonsei Med J*. 2018;59(1):4–12.
9. Derosa L, Hellmann MD, Spaziano M, et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. *Ann Oncol*. 2018;29(6):1437–44.
10. Belluomini L, Caldart A, Avancini A, et al. Infections and Immunotherapy in Lung Cancer: A Bad Relationship? *Int J Mol Sci*. 2021;22(1):42.
11. Lurienne L, Cervesi J, Duhalde L, et al. NSCLC Immunotherapy Efficacy and Antibiotic Use: A Systematic Review and Meta-Analysis. *J Thorac Oncol*. 2020;15(7):1147–59.
12. Zhao S, Gao G, Li W, et al. Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer. *Lung Cancer*. 2019;130:10–7.
13. Tiberi S, du Plessis N, Walzl G, et al. Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies. *Lancet Infect Dis*. 2018;18(7):e183–98.
14. Takata S, Koh G, Han Y, et al. Paradoxical response in a patient with non-small cell lung cancer who received nivolumab followed by anti-Mycobacterium tuberculosis agents. *J Infect Chemother*. 2019;25(1):54–8.


15. Chu YC, Fang KC, Chen HC, et al. Pericardial Tamponade Caused by a Hypersensitivity Response to Tuberculosis Reactivation after Anti-PD-1 Treatment in a Patient with Advanced Pulmonary Adenocarcinoma. *J Thorac Oncol.* 2017;12(8):e111–4.
16. van Eeden R, Rapoport BL, Smit T, et al. Tuberculosis Infection in a Patient Treated With Nivolumab for Non-small Cell Lung Cancer: Case Report and Literature Review. *Front Oncol.* 2019;9:659.
17. Inthasot V, Bruyneel M, Muylle I, et al. Severe pulmonary infections complicating nivolumab treatment for lung cancer: a report of two cases. *Acta Clin Belg.* 2020;75(4):308–10.
18. Kim TH, Kim J. A Case of Toxic Hepatic Event Occurring in Combination Treatment with Nivolumab and Anti-Tuberculosis in Advanced Lung Cancer. *J Thorac Oncol.* 2018;13(10):1034.
19. He W, Zhang X, Li W, et al. Activated pulmonary tuberculosis in a patient with melanoma during PD-1 inhibition: a case report. *Onco Targets Ther.* 2018;24(11):7423–7.
20. Picchi H, Mateus C, Chouaid C, et al. Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatment. *Clin Microbiol Infect.* 2018;24(3):216–8.
21. Tetikkurt Seza T, Faruk E, Funda, et al. Significant Neutrophilic Emperipolesis in Squamous Cell Carcinoma. *Case Rep Oncol Med.* 2018;13:1301562.
22. Barber DL, Sakai S, Kudchadkar RR, et al. Tuberculosis following PD-1 blockade for cancer immunotherapy. *Sci Transl Med.* 2019;11(475):eaat2702.
23. Guidelines for treatment of drug-susceptible tuberculosis and patient care. 2017 update. Geneva: World Health Organization, April 2017 [https://www.who.int/tb/publications/2017/dstb\\_guidance\\_2017/en/](https://www.who.int/tb/publications/2017/dstb_guidance_2017/en/).
24. Nahid P, Dorman SE, Alipanah N, et al. Executive Summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. *Clin Infect Dis.* 2016;63(7):853–67.

## Figures




**Figure 1**

CT (chest computed tomography) comparison of the patients at different stages. A, 2020-07-13, initial discovery of lung mass lesion; B, 2020-12-11, after 3 months of anti-TB (tuberculosis); C, 2021-02-03, after 2 cycles of Pembrolizumab.




**Figure 2**

The Histological examination film of the right lower lung lesion by CT-guided percutaneous lung biopsy showed infiltration of glandular tissues, indicating the possibility of non-small cell lung cancer (NSCLC) transforming into adenocarcinoma. Hematoxylin eosin stain(HE), A×200. Immunohistochemical technique, B×100, antigen Ki-67 (60%); C×100, thyroid transcription factor 1 (TTF-1) (+++); D×100, cytokeratin (CK7) (+++); E×100, F×200, programmed cell death protein ligand 1 (PD-L1) (60%).



**Figure 3**

The gastric body under Gastroscopic at three different times in this patient. A, 2020-07-28, before anti-tuberculous treatment; B, 2020-12-12, after 3 months of anti-tuberculous; C, 2021-02-03, after 2 cycles of Pembrolizumab; D×100, programmed cell death protein ligand 1 (PD-L1) (90%).



**Figure 4**

Clinical course from the time of anti-TB to combined with Pembrolizumab in this patient. ALT, glutamic-pyruvic transaminase; AST, glutamic oxalacetic transaminase; NSE, neuron-specific enolase.